Biogen Inc. (BIIB) |
|
305.15 1.7 (0.56%)
|
11-25 13:00 |
|
Open: |
304.35 |
Pre. Close: |
303.45 |
|
High:
|
307.527 |
Low:
|
302.7 |
|
Volume:
|
470,764 |
Market Cap:
|
43,942(M) |
|
|
|
Technical analysis |
as of: 2022-11-25 1:55:31 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 359.19 One year: 419.53 |
| Support: |
Support1: 279.34 Support2: 261.92 |
| Resistance: |
Resistance1: 307.52 Resistance2: 359.19 |
| Pivot: |
295.72 |
| Moving Average: |
MA(5): 303.96 MA(20): 292.1
MA(100): 238.47 MA(250): 223.87 |
| MACD: |
MACD(12,26): 11  Signal(9): 11.2 |
| Stochastic oscillator: |
%K(14,3): 93.1 %D(3): 92.2 |
| RSI: |
RSI(14): 71 |
| 52-week: |
High: 307.52 Low: 187.16 |
| Average Vol(K): |
3-Month: 1,662 (K) 10-Days: 1,111 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BIIB ] has closed below upper band by 22.4%. Bollinger Bands are 4.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
307.85 - 309.4 |
309.4 - 310.68 |
|
Low:
|
298.51 - 300.16 |
300.16 - 301.51 |
|
Close:
|
301.04 - 303.62 |
303.62 - 305.73 |
|
Company Description |
|
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Thu, 24 Nov 2022
Why Is Biogen Inc. (BIIB) Up 8.2% Since Last Earnings Report? - Yahoo Finance
Wed, 23 Nov 2022
BIIB or RGEN: Which Is the Better Value Stock Right Now? - Nasdaq
Wed, 23 Nov 2022
Noteworthy ETF Inflows: RSP, BIIB, NFLX, ABMD - Nasdaq
Mon, 21 Nov 2022
Notable Monday Option Activity: BIIB, LCID, MA - Nasdaq
Thu, 17 Nov 2022
Is Biogen (BIIB) a Great Value Stock Right Now? - Yahoo Finance
Mon, 14 Nov 2022
Notable Monday Option Activity: IFF, PM, BIIB - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
144 (M) |
| Shares Float |
144 (M) |
|
% Held by Insiders
|
0.6 (%) |
|
% Held by Institutions
|
88.3 (%) |
|
Shares Short
|
2,470 (K) |
|
Shares Short P.Month
|
2,710 (K) |
Stock Financials |
|
EPS
|
19.62 |
|
EPS Est Next Qtl
|
5.78 |
|
EPS Est This Year
|
22.1 |
|
EPS Est Next Year
|
23.81 |
|
Book Value (p.s.)
|
88.72 |
|
Profit Margin (%)
|
27.6 |
|
Operating Margin (%)
|
28.5 |
|
Return on Assets (ttm)
|
7.5 |
|
Return on Equity (ttm)
|
20.2 |
|
Qtrly Rev. Growth
|
-9.7 |
|
Gross Profit (p.s.)
|
61.59 |
|
Sales Per Share
|
71.94 |
|
EBITDA (p.s.)
|
24.23 |
|
Qtrly Earnings Growth
|
253.1 |
|
Operating Cash Flow
|
2,400 (M) |
|
Levered Free Cash Flow
|
2,310 (M) |
Stock Valuations |
|
PE Ratio
|
15.55 |
|
PEG Ratio
|
-4.2 |
|
Price to Book value
|
3.43 |
|
Price to Sales
|
4.24 |
|
Price to Cash Flow
|
18.3 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
